New sublingual drug aims to make opioid withdrawal less painful
NCT ID NCT05712707
First seen Jan 11, 2026 · Last updated May 08, 2026 · Updated 23 times
Summary
This study tests a new sublingual film (BXCL501) containing dexmedetomidine, a non-opioid drug, to reduce withdrawal symptoms in people with opioid use disorder. About 160 adults who are physically dependent on opioids will receive BXCL501, lofexidine, or a placebo during a 7-day inpatient detox. The goal is to see if BXCL501 is safer and more effective than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel HRI
Marlton, New Jersey, 08053, United States
-
Clinilabs
Eatontown, New Jersey, 07724, United States
-
New York State Psychiatric Institute
New York, New York, 10032, United States
-
Yale University
New Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.